|Interview: How 4.5MM Late-Stage Neuro Patients Drive Opportunity For MRI Interventions|
|By Staff and Wire Reports|
|Tuesday, 18 September 2012 13:32|
2.2 Million late-stage neuro-patients are "stranded", according to MRI Interventions (OTCBB:MRIC) CEO Kimble Jenkins, who explains that neurosurgeons have been performing minimally invasive brain surgeries using technologies dating back at least 60 years."The surgeons essentially perform these procedures blind," says Jenkins, whose company has developed a next-generation imaging platform that allows neurosurgeons to see inside a patient's brain in real-time during procedures.
The company hopes to revolutionize neurosurgery using MRI imaging similar to how the endoscope revolutionized orthopedic surgery or how fluoroscopy changed the dynamics of cardiovascular procedures.
Companies such as CellDex Therapeutics (NASDAQ:CLDX), ImmunoCellular Therapeutics (AMEX:IMUC) or Agenus (NASDAQ:AGEN), who are developing experimental therapies targeting brain tumors, can utilize MRI Interventions’ technology as a direct delivery platform for their drugs. In facilitating the delivery of these, and other, experimental therapies, MRI Interventions creates risk-mitigated exposure to the future of treating neurologic diseases. As an intermediary in the delivery of therapeutics, MRI Interventions benefits from the recurring use of its technology, which drives revenues and cash-flows.
In an exclusive video interview, MRI Interventions Chief Executive Officer, Kimble Jenkins, discusses the company's outlook and growth prospects, utilization of ClearPoint - the company's MRI-guided visualization platform - and research & development efforts, particularly a next-generation visualization platform that will guide surgeons in catheter-based cardiac EP procedures.